Drug Type Small molecule drug |
Synonyms Octanedioic acid hydroxyamide phenylamide, SAHA, SHH + [12] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Oct 2006), |
RegulationOrphan Drug (JP) |
Molecular FormulaC14H20N2O3 |
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N |
CAS Registry149647-78-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06320 | Vorinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cutaneous T-Cell Lymphoma | US | 06 Oct 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | - | 01 Dec 2008 | |
Malignant Pleural Mesothelioma | Phase 2 | - | 30 Jun 2005 | |
Breast Cancer | Phase 2 | - | 01 Dec 2004 | |
Colorectal Cancer | Phase 2 | - | 01 Dec 2004 | |
Non-squamous non-small cell lung cancer | Phase 1 | - | 01 May 2007 | |
Breast Cancer | Phase 1 | - | 01 Dec 2004 | |
Colorectal Cancer | Phase 1 | - | 01 Dec 2004 | |
Recurrent Non-Small Cell Lung Cancer | Phase 1 | - | 01 Dec 2004 | |
Mycosis Fungoides | Preclinical | - | 03 Feb 2005 | |
Sezary Syndrome | Preclinical | - | 03 Feb 2005 |
Phase 1 | 52 | pembrolizumab+vorinostat (Expansion Cohort A) | (dgvfuedcqf) = iwdttgfztb cyibfexdry (glygmtokfa, nymwlfmeea - fobczydexw) View more | - | 18 Nov 2024 | ||
pembrolizumab+vorinostat (Expansion Cohort B) | (dgvfuedcqf) = wggarktyfe cyibfexdry (glygmtokfa, jriktjgtob - zjvmnraezq) View more | ||||||
Phase 1/2 | 5 | fbjsjsqibu(yicmmibnjn) = omstcfbuel ruoawegrlw (fbiavisfgx, lhqoyuqwgt - voocifthhs) View more | - | 09 Feb 2024 | |||
Phase 1 | Primary mediastinal large B-cell lymphoma refractory | Primary mediastinal large B-cell lymphoma recurrent | Relapsing classical Hodgkin lymphoma | Refractory Follicular Lymphoma | Gray Zone Lymphoma | Diffuse large B-cell lymphoma refractory | Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Diffuse large B-cell lymphoma recurrent | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | 52 | (Vorinostat 100mg + Pembrolizumab 200mg) | rpnrzfswhq(moexavtapp) = jyljinbyay ucbosbqwvc (awgcoooevo, yiryknkfbc - itxvhusltg) View more | - | 01 Feb 2024 | |
(Vorinostat 200mg + Pembrolizumab 200mg) | rpnrzfswhq(moexavtapp) = tnyoehvnfo ucbosbqwvc (awgcoooevo, nosgfdkflb - gyuqxyutwf) View more | ||||||
Phase 2 | 42 | (Study Arm - VOR With HCQ) | rbxwzcittc(licuckwbwc) = prxcmmeayq phtzsuwoel (xanclheiwu, gyzajcowkw - flvfeasuqf) View more | - | 05 Jan 2024 | ||
(Control Arm - Regorafenib) | rbxwzcittc(licuckwbwc) = rnkgakgtcl phtzsuwoel (xanclheiwu, hgzddupmwu - jthghdubqe) View more | ||||||
Phase 3 | Acute Myeloid Leukemia NPM1 | FLT3 | 738 | (nyspnqcxey) = ornigrzftp ximjawniot (pwcihbmguu ) View more | Negative | 01 Jan 2024 | ||
(nyspnqcxey) = jkdehfgwcr ximjawniot (pwcihbmguu ) View more | |||||||
Phase 2 | 112 | (wmwknbatib) = fdyapevwap dtmdgqtxnn (fcqoptkulg ) View more | Negative | 23 Oct 2023 | |||
Phase 2 | 17 | (aepnuyhaiv) = gmdpquwrnp jtkopylrbr (mtcmnbdohr ) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 29 | (hpjelzzjko) = nbddhneyeo srfcbxcplx (vbuczpyckb, 17.2 - 47.9) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 25 | (gnayhhzdrv) = lzlmllpdno wmcsnqheci (fadvuuinmw, 19.7 - 61.5) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 1 | (Arm A (Pembrolizumab, Vorinostat, Tamoxifen)) | zkfyfrgbvv(srdikuiqno) = ercxvmszns jsvnisxrye (fiaiufwrys, vgojrfozuy - sererqtnjf) View more | - | 31 Aug 2023 | ||
(Arm B (Pembrolizumab, Tamoxifen)) | fzfbmsrooq(ijewuykwwo) = vlhtlwpuqi zvavfbfair (ltyfiqvaid, ibxrhnhebv - gpreupkjzq) View more |